Benefits of PT-141 PT-141 is an FDA-approved drug for the treatment of HSDD and has been extensively tested in several Phase 2 and Phase 3 clinical trials
GLP-1 helps to regulate blood sugar levels by stimulating insulin secretion, reducing glucagon secretion, and slowing the rate at which the stomach empties
Secondary goals often include improvements in obesity-related comorbidities such as hypertension, dyslipidemia, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD)
By helping control blood sugar levels, semaglutide can reduce the risk of complications from diabetes, such as heart disease, kidney damage, and nerve damage
However, disruption of this pathway, particularly due to insulin resistance, can lead to impaired glucose utilization, oxidative stress, reduced GABA levels, and increased neuronal excitability, which ultimately contributes to seizure susceptibility and epileptogenesis [Table 3]